ArticleJournal of medical biochemistry2025
Diagnostic value of serum levels of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), IL-6, TNF-a, and IL-1b in preserving kidney function in diabetic renal cell carcinoma patients undergoing partial resection: A focus on the TGF-b1/Smad pathway.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Malondialdehyde-Superoxide Dismutase Redox Imbalance as an Early Biological Risk Indicator in Young Adult Smokers.Vascular health and risk management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the protective effects of dexmedetomidine (DEX) on renal damage in diabetic patients with renal cell carcinoma undergoing partial nephrectomy. Specifically, it focused on oxidative stress markers, inflammatory cytokines, and the TGF-b1/Smad signalling pathway. Methods: Between August 2022 and July 2024, 100 diabetic patients with renal cell carcinoma undergoing partial nephrectomy were randomly assigned to receive either 1.0 mg/kg of DEX or normal saline (control) during surgery. Blood samples were taken preoperatively, intraoperatively, and postoperatively to measure oxidative stress markers (malondialdehyde [MDA], superoxide dismutase [SOD], glutathione peroxidase [GSH-Px]), inflammatory cytokines (IL-6, TNF-a, IL-1b), and renal function indicators (BUN, Scr, CysC). The TGF-b1/Smad pathway and renal cell apoptosis were also assessed. Results: No significant differences in baseline markers were observed between the groups. However, during and after surgery, the DEX group exhibited significantly lower MDA levels and higher SOD and GSH-Px levels (P<0.05), indicating reduced oxidative stress. Inflammatory markers (IL-6, TNF-a, IL-1b) were also lower in the DEX group. Conclusions: DEX significantly mitigates renal damage in diabetic patients undergoing partial nephrectomy by reducing oxidative stress, inflammation, and apoptosis and by inhibiting the TGF-b1/Smad pathway. These findings suggest its potential as a protective agent for high-risk surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.